Liposomal irinotecan pre-emptive dose reduction in patients with pancreatic ductal adenocarcinoma: 667 patients' experience within a population-based study.
2021
Background:Liposomal irinotecan (nal-IRI) plus 5-fluorouracil and leucovorin (5-FU/LV) is currently the standard second-line treatment for patients with pancreatic ductal adenocarcinoma (PDAC) afte...
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
27
References
0
Citations
NaN
KQI